Next Article in Journal
Full-Genome Sequences and Phylogenetic Analysis of Archived Danish European Bat Lyssavirus 1 (EBLV-1) Emphasize a Higher Genetic Resolution and Spatial Segregation for Sublineage 1a
Next Article in Special Issue
Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned
Previous Article in Journal
Development and Characterization of a cDNA-Launch Recombinant Simian Hemorrhagic Fever Virus Expressing Enhanced Green Fluorescent Protein: ORF 2b’ Is Not Required for In Vitro Virus Replication
Previous Article in Special Issue
Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2
Communication

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

1
Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong 30019, Korea
2
Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea
3
Department of Lab Medicine, College of Medicine, Korea University, Seoul 02841, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Luis Martinez-Sobrido
Viruses 2021, 13(4), 633; https://doi.org/10.3390/v13040633
Received: 19 March 2021 / Revised: 4 April 2021 / Accepted: 5 April 2021 / Published: 7 April 2021
A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization efficiency of SARS-CoV-2 spike pseudoviruses bearing particular mutations of the receptor-binding domain (RBD) derived either from the Wuhan strains (referred to as D614G or with other sites) or the B.1.351 lineage (referred to as N501Y, K417N, and E484K). The three different pseudoviruses B.1.351 lineage related significantly increased infectivity compared with other mutants that indicated Wuhan strains. Interestingly, K417N and E484K mutations dramatically enhanced cell–cell fusion than N501Y even though their infectivity were similar, suggesting that K417N and E484K mutations harboring SARS-CoV-2 variant might be more transmissible than N501Y mutation containing SARS-CoV-2 variant. We also investigated the efficacy of two different monoclonal antibodies, Casirivimab and Imdevimab that neutralized SARS-CoV-2, against several kinds of pseudoviruses which indicated Wuhan or B.1.351 lineage. Remarkably, Imdevimab effectively neutralized B.1.351 lineage pseudoviruses containing N501Y, K417N, and E484K mutations, while Casirivimab partially affected them. Overall, our results underscore the importance of B.1.351 lineage SARS-CoV-2 in the viral spread and its implication for antibody efficacy. View Full-Text
Keywords: SARS-CoV-2; B.1.351; K417N and E484K mutation of spike; viral infectivity; neutralization; Casirivimab; Imdevimab SARS-CoV-2; B.1.351; K417N and E484K mutation of spike; viral infectivity; neutralization; Casirivimab; Imdevimab
Show Figures

Figure 1

MDPI and ACS Style

Kim, Y.J.; Jang, U.S.; Soh, S.M.; Lee, J.-Y.; Lee, H.-R. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Viruses 2021, 13, 633. https://doi.org/10.3390/v13040633

AMA Style

Kim YJ, Jang US, Soh SM, Lee J-Y, Lee H-R. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Viruses. 2021; 13(4):633. https://doi.org/10.3390/v13040633

Chicago/Turabian Style

Kim, Yeong J., Ui S. Jang, Sandrine M. Soh, Joo-Youn Lee, and Hye-Ra Lee. 2021. "The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus" Viruses 13, no. 4: 633. https://doi.org/10.3390/v13040633

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop